AC Immune SA (ACIU) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

AC Immune SA (ACIU)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.61

0.00 (0.00%)

At close: Jan 14, 2025, 3:59 PM

2.61

0.00%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	2.6
Market Cap	260.17M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.42
PE Ratio (ttm)	-6.21
Forward PE	n/a
Analyst	Buy

Ask	2.98
Volume	169,706
Avg. Volume (20D)	129,378
Open	2.64
Previous Close	2.61
Day's Range	2.60 - 2.83
52-Week Range	2.25 - 4.98
Beta	undefined

About ACIU

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The comp...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 23, 2016

Employees 133

Stock Exchange NASDAQ

Ticker Symbol ACIU

Website https://www.acimmune.com

Analyst Forecast

According to 2 analyst ratings, the average rating for ACIU stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 359.77% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

AC Immune SA is scheduled to release its earnings on Mar 13, 2025, before market opens.
Analysts project revenue of $556.43K, reflecting a -96.67% YoY shrinking and earnings per share of -0.19, making a 216.67% increase YoY.

Why Price Moved

2 months ago · Source

+13.42%

AC Immune shares are trading higher after the comp... Unlock content with Pro Subscription

4 months ago · Source

+5.81%

AC Immune shares are trading higher after the company announced it will receive the second ReTain-related milestone payment under its agreement with Janssen Pharmaceuticals.

News

2 months ago · benzinga.com

AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients

AC Immune SA ACIU revealed data from a Phase 2 clinical trial of its wholly owned anti-alpha-synuclein (a-syn) active immunotherapy candidate for early Parkinson's disease.